
1-2023

Center for Biomedical Research at the Population Council

Population Council

Follow this and additional works at: https://knowledgecommons.popcouncil.org/series_newsletters_factsheets

How does access to this work benefit you? Let us know!

Recommended Citation

"Center for Biomedical Research at the Population Council," factsheet. New York: Population Council, 2022.

This Fact Sheet is brought to you for free and open access by the Population Council.

Center for Biomedical Research

at the Population Council

We are a **global product development partnership** committed to improving public health. We develop and ensure access to new and affordable products that promote sexual and reproductive health, rights, and choices for people in low- and middle-income countries.

The Center for Biomedical Research (CBR) addresses critical questions in sexual and reproductive health and develops innovative products that protect the health and well-being of millions of people worldwide.

CBR is located at Rockefeller University in New York City and leverages global partnerships with industry and academia, as well as synergistic collaborations with the Population Council's international offices and affiliates and an expansive social and behavioral research program.


In 2022, the Council acquired the monthly dapivirine vaginal ring and other HIV prevention technologies from the International Partnership for Microbicides. The acquisition expands CBR's product portfolio, solidifying our position as the leading innovator of high quality sexual and reproductive health (SRH) products that enhance choice for individuals in the global market.

Our Vision



CBR offers:

- The most robust product pipeline in sexual and reproductive health of any organization globally, with products at every stage of development for contraception, HIV, and multipurpose use.
- Unparalleled professional expertise in product formulation development, pre-clinical development, good manufacturing practices (GMP) manufacturing, clinical development, regulatory affairs, and product introduction.
- Extensive networks and partnerships are utilized throughout the product development and market introduction processes. This includes partnerships with academia, research and clinical trial networks, policymakers, the pharmaceutical industry, manufacturers, product distributors, and implementers. All of which help to ensure our products are introduced and accessible worldwide.
- Efficient and effective management and operations across research portfolios.



Approved SRH products developed and/or brought to market

Paragard®
Copper T
380A IUD



1984
FDA-approved

10 years
Label
duration

Norplant®
6-rod
Implant



1991
FDA-approved

5 years
Label
duration

Jadelle®
2-rod
Implant



1996
FDA-approved

5 years
Label
duration

Progering®
Vaginal
Ring



1998
Multiple
approvals
3 months
Label
duration

Mifeprex®
Early Option
Pill



2000
FDA-approved

N/A
Label
duration

Mirena®
Levonorges-
trel IUS



2000
FDA-approved

8 years
Label
duration

Annovera®
Vaginal
System



2018
FDA-approved

12 months
Label
duration

Dapivirine®
Vaginal
Ring



2020
EMA positive
opinion
1 month
Label
duration

Our Impact

170 million women

Estimated to be currently using a Council-developed contraceptive product

10

Biomedical
product
approvals

20

US patents and FDA
applications since 2009

24

Clinical trials initiated
since 2010

5

Laboratories based at
Rockefeller University

107

Research fellows, representing
29 countries, between 2010–2020

28

Peer-reviewed publications in
high-impact journals in 2021

Products in the Pipeline

Contraception (F)	Contraception (M)	HIV	MPT	Other
Nestorone® and Estradiol Vaginal Ring Pregnancy prevention	Nestorone® + Testosterone Gel (NES/T Gel) Male contraception	Dapivirine Vaginal Ring (3-month DPV) HIV prevention	Dapivirine Vaginal Ring with Levonorgestrel (DPV-LNG) Pregnancy and HIV prevention	Nestorone® for Multiple Sclerosis Remyelination therapy
2nd-Generation Annovera® Pregnancy prevention			Dual Prevention Pill Pregnancy and HIV prevention	
Nestorone® Vaginal Ring Postpartum Pregnancy prevention			Etonogestrel, Ethinyl Estradiol, & Q-Griffithsin (EEQ IVR) Pregnancy and HIV prevention	
Weekly Mifepristone Pill Pregnancy prevention			Griffithsin FDI HIV, HSV-2, and HPV prevention	
			Nonhormonal Contraceptive & Q-Griffithsin MPT FDI Pregnancy, HIV, STIs, and bacterial vaginosis prevention	
			Non-hormonal IVR Pregnancy, HIV, STIs, and BV prevention	

Clinical | Preclinical

Ring

Gel

Fast-dissolving insert

Injectable

Microneedle

Tablet